Not exact matches
«Since it's impossible to predict which
of these agents will cause the next epidemic, it would be ideal to develop a single therapy that could treat or prevent infection caused by any known ebolavirus,» says study co-leader Zachary A. Bornholdt, Ph.D.,
director of antibody discovery at Mapp Biopharmaceutical, Inc. «Our discovery and characterization
of broadly neutralizing
human antibodies is an important step toward that goal,» adds study co-leader, Kartik Chandran, Ph.D., professor
of microbiology & immunology at Albert Einstein College
of Medicine.
«The quality
of these naturally occurring
human antibodies as biological drugs to treat the virus infection is remarkable, and we are doubly encouraged because they recognize multiple species
of Ebola,» said immunologist James Crowe,
Director of the Vanderbilt Vaccine Center.
Anthony Fauci,
director of the National Institute
of Allergy and Infectious Diseases, called the new work a «significant advance,» noting in a statement that it «opens the way to producing [monoclonal
antibodies] that potentially could be used diagnostically or therapeutically» for the flu as well as other infectious diseases such as hepatitis C and the
human immunodeficiency virus (HIV), which can lead to full - blown AIDS.
«This is an important demonstration
of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production
of antibodies of major relevance to
human cancer,» said David B. Weiner, Ph.D., executive vice president
of The Wistar Institute,
director of The Wistar Institute Vaccine & Immunotherapy Center, W.W. Smith Charitable Trust Professor in Cancer Research, and senior author
of the study.
This new work suggests that anti-PD-1
antibodies might be equally effective in treating hepatitis C and other persistent
human viral infections, says Christopher Walker, PhD, a senior author on the study and
director of the Center for Vaccines and Immunity at Nationwide Children's.